ARS Pharmaceuticals SPRY
NASDAQ SPRY
$4.07 -0.05 (-1.21%)
At close: Oct 2, 2026 · 4:00 PM EDT

ARS Pharmaceuticals (SPRY) Other Accumulated Expenses (2024 - 2026)

Updated

ARS Pharmaceuticals' Other Accumulated Expenses came in at $13.48 million for Q2 2026, down 34.0% from the prior quarter.

Analysis

ARS Pharmaceuticals (SPRY) Other Accumulated Expenses (2024 - 2026) Analysis & Trends

At the end of FY2025, ARS Pharmaceuticals' Other Accumulated Expenses was $6.88 million, up 69.2% from FY2024.

  • Going back by year, Other Accumulated Expenses was $4.07 million in FY2024.
  • The five-year range for quarterly Other Accumulated Expenses is $4.07 million (Q4 2024) to $20.41 million (Q1 2026).
  • Business Quant data shows SPRY's Other Accumulated Expenses at $20.41 million (Q1 2026), $6.88 million (Q4 2025) and $11.27 million (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 ARS Pharmaceuticals 404.71 Mn 260.91 Mn 20.81 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 13.48 Mn
Mar 31, 2026 20.41 Mn
Dec 31, 2025 6.88 Mn
Sep 30, 2025 11.27 Mn
Dec 31, 2024 4.07 Mn
API Access

ARS Pharmaceuticals Other Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=SPRY&period=max&api_key=YOUR_API_KEY